Shimadzu’s new member of the UFMS (Ultra-Fast Mass Spectrometry) family in Europe, the LCMS-8045 offers an optimum balance of sensitivity, robustness, and cost-effectiveness to laboratories performing demanding routine quantitative analyses in areas such as food safety and environmental testing. Ultra-fast technologies improve data acquisition and ensure highly reproducible data even for the most complex matrices. Shimadzu’s LabSolutions software provides options to address specific customer requirements. In case of new challenges or applications requiring higher sensitivity, the LCMS-8045 can be upgraded to the high-sensitivity LCMS-8060.
Shimadzu Europa GmbH
Albert-Hahn-Strasse 6-10
47269 Duisburg, Germany
phone: +49 (0) 203-7687-0
shimadzu@shimadzu.euwww.shimadzu.eu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.